Crowdonomics
All companies
NAVIX HEALTH logo

NAVIX HEALTH

Operating

Navix Health, Inc.

Healthcare · Austin, TX · Founded 2021

Seamless behavioral health solutions

Post-money valuation ⓘ
$7.7M
As of Sep 2024 · from Reg CF Offering (2024) · pre-money + amount raised, not a traded price
Total raised
$1,504,664
Crowd $125K · Private $1.4M · 2 rounds since 2024
Latest share price
$0.48
Reg CF · Common Stock · Jun 2024 offering price

Financials

FY2022–FY2023 · from SEC filings · hover any figure for its source
$5K
−$211K
2022
$28K
−$367K
2023
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2022 reviewed
FY2023 reviewed
Income statement
Revenue
$4,900
$28,210
Cost of goods sold
$0
$0
Gross margin
100%
100%
Net income
-$211,057
-$366,678
Taxes paid
$0
$0
Balance sheet
Cash
$110,678
$179,870
Accounts receivable
$0
$0
Total assets
$414,964
$828,616
Short-term debt
$175,478
$355,577
Long-term debt
$0
$0
Total liabilities
$175,478
$355,577
Other
Headcount
—
25

Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.

Valuation over rounds

Pre-money — the valuation set before each round’s money came in
$7.5M
pre-money
Reg CF · Common · Jun 2024

Blue bars are the pre-money valuation the company stated for a priced round.

Share price over rounds

$0.48$0.24$0.4382
May 2024Jun 2024
Round offering price or verified disclosed saleDisclosed sale, unverified or year-only

Disclosed sales come from the issuer's own filings (prior-offering lines, audited-statement notes) and are amount ÷ securities sold. A down round is a firm point more than 25 % below the previous firm point of the same share class on a comparable basis; the comparison ignores unverified and year-only lines.

Fundraising history

Raised $125K / $1.2MInvestors 181Post-money $7.7M

Team

4 people
Jason Brumback
Founder, Chief Executive Officer, and Director

Jason Brumback sold his construction & real estate businesses to establish successful behavioral health facilities in Southern California. Through his work, he recognized the needs of the industry & developed Navix Health. He also co-founded Resurface Group, offering in-home clinical services, Mental Health Transitions & Resurface Psychiatric. In addition to spending about 95% of his time working for Navix Health, Jason also serves as CEO of Resurface Group, LLC, spending only a few hours a week attending executive meetings.

Colin Christie
Chief Technology Officer and Director

Colin Christie, CTO of Navix Health Inc., brings decades of executive experience. He co-founded successful ventures like MxSecure, Inc. and Lifetrack Medical Systems Inc., securing significant funding and global expansion. Colin holds a degree in Chemical Engineering from UC Berkeley.

Kristen Smith
Chief Marketing Officer

Kristen has 18+ years of experience managing marketing, admissions, & communications for mental health & substance abuse facilities across the US. With a background in advertising & a degree in Business Marketing from Texas Christian University, she understands the importance of seamless communication & operations in healthcare settings.

Megan Weaver
Vice President and Chief Product Officer

With 19+ years in behavioral healthcare, Megan specializes in admissions, operations, and compliance. She holds a Diploma in Alcohol and Drug Counseling Studies and a BA in Communication Studies from Chapman University, also earning SHRM-CP certification. adept at strategic expansion and accreditation processes.

Names and titles as disclosed on SEC Form C, StartEngine. Bios and photos come from the platform campaign page and may be out of date.

Reg CF annual-report compliance

Delinquent

Filed 0 of 2 annual reports (FY2024–FY2025)

Missing: 2024, 2025

181 investors
holder-count proxy

Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.

SEC filings

  • Form C-UOct 28, 20240001665160-24-001474
    EDGAR
  • Form CJun 27, 20240001665160-24-001030
    EDGAR
Source: ManualCIK 0002025949DEShare price $0.48

About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.